Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Radiopharm Theranostics begins third-cohort enrolment in Phase 1 177Lu-RAD204 trial targeting PD-L1 tumours Find out how Radiopharm Theranostics is advancing 177Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial. bySoujanya RaviNovember 12, 2025